Literature DB >> 19569232

The CDH1-160C>A polymorphism is a risk factor for colorectal cancer.

Alan M Pittman1, Philip Twiss, Peter Broderick, Steven Lubbe, Ian Chandler, Steven Penegar, Richard S Houlston.   

Abstract

Part of the inherited susceptibility to colorectal cancer (CRC) is caused by the coinheritance of common low risk variants. E-cadherin (CDH1) has an established role in CRC; somatic inactivation of CDH1 is a common early event, and germline mutations can cause early-onset CRC. The -160C>A promoter variant (rs16260) of CDH1 has been reported to influence CDH1 transcription and thereby represents a strong candidate for a predisposition locus. To examine this proposition, we conducted a two-staged association study based on genotyping a total of 5,679 CRC cases and 5,412 controls for rs16260. CDH1-160C>A genotype was associated with CRC risk (p(trend) = 0.001). Compared to common homozygotes, the odds ratios (ORs) of CRC associated with heterozygous and homozygote variant genotype were 0.90 (95% confidence interval [CI]: 0.84-0.97) and 0.81 (95% CI: 0.71-0.93), respectively. In combination with the previously identified 8q21, 8q24, 10p14, 11q, 15q13.3 and 18q21 risk variants, the risk of CRC increases with an increasing numbers of variant alleles for the 7 loci (OR(per allele) = 1.16; 95% CI: 1.13-1.19; p(trend) = 1.68 x 10(-34)). These data indicate CDH1-160C>A is a risk factor for CRC, and because a high proportion of the European population are carriers of at-risk genotypes, the variant is likely to contribute substantially to the development of CRC. Furthermore, our study underscores the importance of conducting association studies using large sample series to demonstrate polymorphic variants conferring modest relative risks.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19569232     DOI: 10.1002/ijc.24542

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  rs17501976 polymorphism of CLDN1 gene is associated with decreased risk of colorectal cancer in a Chinese population.

Authors:  Jian-Jun Chen; Ming Zhong; Tong-Hai Dou; Zhi-Yong Wu; Wei-Jun Tang
Journal:  Int J Clin Exp Med       Date:  2015-01-15

2.  Role of rare variants in undetermined multiple adenomatous polyposis and early-onset colorectal cancer.

Authors:  Jérémie H Lefevre; Carolina Bonilla; Chrystelle Colas; Bruce Winney; Elaine Johnstone; Susan Tonks; Tammy Day; Katarzyna Hutnik; Abdelhamid Boumertit; Florent Soubrier; Rachel Midgley; David Kerr; Yann Parc; Walter F Bodmer
Journal:  J Hum Genet       Date:  2012-08-09       Impact factor: 3.172

3.  E-cadherin (CDH1) gene promoter polymorphism and the risk of colorectal cancer : a meta-analysis.

Authors:  Yadong Wang; Haiyan Yang; Li Li; Haiyu Wang; Congke Zhang; Xiangqun Xia
Journal:  Int J Colorectal Dis       Date:  2011-10-14       Impact factor: 2.571

4.  Fine-mapping of colorectal cancer susceptibility loci at 8q23.3, 16q22.1 and 19q13.11: refinement of association signals and use of in silico analysis to suggest functional variation and unexpected candidate target genes.

Authors:  Luis G Carvajal-Carmona; Jean-Baptiste Cazier; Angela M Jones; Kimberley Howarth; Peter Broderick; Alan Pittman; Sara Dobbins; Albert Tenesa; Susan Farrington; James Prendergast; Evi Theodoratou; Rebecca Barnetson; David Conti; Polly Newcomb; John L Hopper; Mark A Jenkins; Steven Gallinger; David J Duggan; Harry Campbell; David Kerr; Graham Casey; Richard Houlston; Malcolm Dunlop; Ian Tomlinson
Journal:  Hum Mol Genet       Date:  2011-04-29       Impact factor: 6.150

5.  The epithelial cadherin -160C/A polymorphism is associated with decreased risk of colorectal cancer: a case-control study.

Authors:  Wenhuan Li; Deshuang Xiao; Huawen Wu; Lewei Xu
Journal:  Clin Exp Med       Date:  2019-10-17       Impact factor: 3.984

6.  Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival.

Authors:  Christopher G Smith; David Fisher; Rebecca Harris; Timothy S Maughan; Amanda I Phipps; Susan Richman; Matthew Seymour; Ian Tomlinson; Dan Rosmarin; David Kerr; Andrew T Chan; Ulrike Peters; Polly A Newcomb; Shelley Idziaszczyk; Hannah West; Angela Meade; Richard Kaplan; Jeremy P Cheadle
Journal:  Clin Cancer Res       Date:  2015-04-14       Impact factor: 12.531

7.  Contribution of the -160C/A polymorphism in the E-cadherin promoter to cancer risk: a meta-analysis of 47 case-control studies.

Authors:  Lin Wang; Guiying Wang; Chenqi Lu; Bo Feng; Jiuhong Kang
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

8.  Identification of genes expressed by immune cells of the colon that are regulated by colorectal cancer-associated variants.

Authors:  Vanya D Peltekova; Mathieu Lemire; Aamer M Qazi; Syed H E Zaidi; Quang M Trinh; Ryszard Bielecki; Marianne Rogers; Lyndsey Hodgson; Mike Wang; David J A D'Souza; Sasan Zandi; Taryne Chong; Jennifer Y Y Kwan; Krystian Kozak; Richard De Borja; Lee Timms; Jagadish Rangrej; Milica Volar; Michelle Chan-Seng-Yue; Timothy Beck; Colleen Ash; Shawna Lee; Jianxin Wang; Paul C Boutros; Lincoln D Stein; John E Dick; Robert Gryfe; John D McPherson; Brent W Zanke; Aaron Pollett; Steven Gallinger; Thomas J Hudson
Journal:  Int J Cancer       Date:  2013-11-13       Impact factor: 7.396

Review 9.  Regulatory Variants and Disease: The E-Cadherin -160C/A SNP as an Example.

Authors:  Gongcheng Li; Tiejun Pan; Dan Guo; Long-Cheng Li
Journal:  Mol Biol Int       Date:  2014-09-02

10.  Might E-cadherin promoter polymorphisms of rs16260 and rs5030625 associate with the risk of nephrolithiasis?

Authors:  Cigdem Donmez; Ece Konac; Batuhan T Aydogan; Cenk Y Bilen
Journal:  Springerplus       Date:  2016-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.